The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ALIGOS THERAPEUTICS INC COM 01626L105   260,125 743,215 SH   DFND 1 0 743,215 0
ARCUTIS BIOTHERAPEUTICS INC COM 03969K108   18,982,304 2,041,108 SH   DFND 1 0 2,041,108 0
BOLT BIOTHERAPEUTICS INC COM 097702104   1,418,600 1,891,467 SH   DFND 1 0 1,891,467 0
EXSCIENTIA PLC ADS 30223G102   3,929,550 770,500 SH   DFND 1 0 770,500 0
INOZYME PHARMA INC COM 45790W108   20,047,035 4,494,851 SH   DFND 1 0 4,494,851 0
IO BIOTECH INC COM 449778109   1,011,110 864,197 SH   DFND 1 0 864,197 0
OCULIS HOLDING AG ORDINARY SHARES H5870P102   19,071,220 1,595,918 SH   DFND 1 0 1,595,918 0
RALLYBIO CORP COM 75120L100   3,222,223 2,404,644 SH   DFND 1 0 2,404,644 0
VAXCYTE INC COM 92243G108   59,882,148 793,036 SH   DFND 1 0 793,036 0
VIGIL NEUROSCIENCE INC COM 92673K108   2,242,380 560,595 SH   DFND 1 0 560,595 0